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Abstract
Introduction The medicinal treatment of osteoarthritis (OA) is
mostly symptomatic to relieve pain and incapacity with
analgesics and non-steroidal anti-inflammatory drugs (NSAIDs),
drugs with well-known risks. Complementary medicines might
reduce the symptoms of OA and decrease the need for NSAIDs.
This study tested the effects of a food supplement, Phytalgic®,
on pain and function in patients with osteoarthritis and their use
of analgesic and NSAIDs.
Methods A randomized double-blind parallel-groups clinical trial
compared Phytalgic® (fish-oil, vitamin E, Urtica dioica) to a
placebo for three months, in 81 patients with OA of the knee or
hip using NSAIDs and/or analgesics regularly. The main
outcome measures were use of NSAIDs (in Defined Daily Doses
per day - DDD/day) or analgesics (in 500 mg paracetamol-
equivalent tablets per week (PET/week) measured each month,
and Western Ontario-McMaster University Osteo-Arthritis Index
(WOMAC) function scales.
Results After three months of treatment, the mean use of
analgesics in the active arm (6.5 PET/week) vs. the placebo arm
(16.5) was significantly different (P < 0.001) with a group mean
difference of -10.0 (95% CI: -4.9 to -15.1). That of NSAIDs in
the active arm (0.4 DDD/day) vs the placebo arm (1.0 DDD/day)
was significantly different (P  = 0.02) with a group mean
difference of - 0.7 DDD/day (95% CI: -0.2 to -1.2). Mean
WOMAC scores for pain, stiffness and function in the active arm
(respectively 86.5, 41.4 and 301.6) vs the placebo arm (resp.
235.3, 96.3 and 746.5) were significantly different (P < 0.001)
with group mean differences respectively of -148.8 (95% CI: -
97.7 to -199.9), -54.9 (95% CI: -27.9 to -81.9) and -444.8
(95% CI: -269.1 to -620.4).
Conclusions The food supplement tested appeared to
decrease the need for analgesics and NSAIDs and improve the
symptoms of osteoarthritis.
Trial registration Clinicaltrials.gov NCT00666523.
Introduction
Osteoarthritis is one of the more common of the chronic
degenerative diseases afflicting an increasingly older popula-
tion. It affects primarily the weight-bearing joints (knee, hip),
causing pain, stiffness and impotence, ultimately crippling
patients and reducing quality of life. There is no curative treat-
ment for this disease, and its final outcome is often joint
replacement of the hip or knee. However, because of the lim-
ited life expectancy of these replacements, they are usually
postponed as much as possible. In the meantime, sympto-
matic pain relief can be obtained with analgesics such as para-
cetamol, or the more effective non-steroidal anti-inflammatory
drugs (NSAIDs) [1-3]. NSAIDs, while generally safe when
used at low doses and short term [4-6], can result in serious
complications (gastrointestinal bleeding, renal failure, coro-
nary heart disease) when used long-term or at higher doses in
BOCF: baseline observation carried forward; DDD: defined daily dose; ITT: intent to treat; NSAIDs: non-steroidal anti-inflammatory drugs; OA: oste-
oarthritis; PET: Paracetamol 500 mg-Equivalent Tablets; SD: standard deviation; WOMAC: Western Ontario-McMaster University Osteo-Arthritis 
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elderly patients, which is often the case in patients with oste-
oarthritis [7-9]. Different products have been proposed for
long-term symptomatic relief of osteoarthritis, some of them
purporting to have some chondroprotective effects, such as
chondroitin sulphate, diacerhein or glucosamine [10-13].
Though meta-analyses are not very encouraging for direct
effects of these adjuncts [14], we found that chondroitin sul-
phate might be associated with less use of analgesics or
NSAIDs [15]. Some food supplements might also have effects
on osteoarthritis symptoms [16-21], but few of these studies
are methodologically valid. Authors have recommended test-
ing fish-oils in patients with arthritis, and supplementation with
minerals such as zinc or selenium, and vitamin E [22].
Patients using one such marketed multi-component food sup-
plement reported reduced use of NSAIDS, at least for some
time. Though it seemed highly unlikely that this supplement
could suppress symptoms of OA, decreasing the use of
NSAIDs might be a desirable objective in these high-risk long-
term users. We therefore performed a randomized double-
blind placebo-controlled clinical trial of this marketed food
supplement, on the use of analgesics and NSAIDs on pain,
stiffness and function scales of osteoarthritis to ensure that
any decrease in analgesic and anti-inflammatory use was not
at the expense of patient function.
Materials and methods
Study design and participants
This was a double-blind, randomized, placebo-controlled, par-
allel-arms clinical trial.
It was approved by the Regional Bordeaux B Committee for
the Protection of Patients, and was registered with clinicaltri-
als.gov (NCT00666523). All patients gave written informed
consent before random assignment to product or placebo.
This study was performed according to all national laws and
regulations governing the conduct of Clinical Trials. It con-
formed to the revised declaration of Helsinki, and to Good
Clinical Practice.
The objective of the study was to test the effects of the food
supplement combination on symptoms of osteoarthritis and on
the use of analgesics and NSAIDs, with the prior hypothesis
that the preparation would decrease the symptoms by an
unspecified amount, and reduce the use of analgesics and
NSAIDs by at least 20% from initial usage.
Patients were considered eligible if they had chronic osteoar-
thritis of the knee or hip (as evidenced from clinical history and
X-ray documentation), experienced pain and/or stiffness
requiring the regular use of NSAIDs, were aged between 40
and 80 years of age, and could demonstrate their capacity to
fill a diary relating their daily treatment.
Patients with inflammatory arthritis, with osteoarthritis not
affecting the knees or hips, with known allergy to any of the
constituents of the study drug, with a life expectancy shorter
than the duration of the study, who were pregnant or lactating,
or who were not legally fit to participate in such a study were
not included.
Osteoarthritis (OA) was diagnosed by the referring rheumatol-
ogist according to the American College of Rheumatology
(ACR) criteria for osteoarthritis of the hip or knee. OA could be
degenerative or post-traumatic.
Study procedures
Undistinguishable numbered treatment units were prepared
according to a randomization list using random block sizes.
Patients were included sequentially. Blinding was lifted only
after database lock.
After a four-week run-in phase during which eligible patients
were trained to use the diary and tested for severity of osteoar-
thritis and use of analgesics or NSAIDs, patients meeting all
inclusion criteria were given blinded, randomized treatment by
the study drug or an indistinguishable placebo, for three suc-
cessive four-week periods. They returned for consultation and
assessment at the end of each period. They filled a diary in
which they indicated each day all medication used (study drug
and other medication). A single investigator within the Depart-
ment of Pharmacology, Université Victor Segalen, Bordeaux,
France followed all patients.
The study was conceived as an add-on study to the usual
symptomatic medication (analgesics and/or NSAIDs).
Patients were asked not to modify the nature of their treatment
for pain and stiffness control and to keep using their usual
analgesic and NSAID medications as often as needed during
the treatment period. The study drug was used in addition to
these medications. Patients were told that they could reduce
the use of their pain and inflammation medication if they did
not feel the need for them, but they had to note all drugs taken
every day in their diary.
The study treatment is a commercially prepared food supple-
ment, Phytalgic®, a marketed preparation which consists of
capsules containing fish oils rich in omega-3 and omega-6
fatty acids, Urtica dioica (the common nettle), zinc and vitamin
E; or an identical placebo. It is produced according to Good
Manufacturing Practices by Phythea laboratories (77176
Savigny le Temple, France).
For the study, the manufacturer provided both the active treat-
ment and the identical placebo, which were prepared in iden-
tical boxes distinguishable only by treatment number
according to the randomisation list provided by the Depart-
ment of Pharmacology Statistics Unit.Available online http://arthritis-research.com/content/11/6/R192
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This preparation was used according to the manufacturer's
recommendations, that is, three capsules per day of study
drug or placebo, one in the morning, two in the evening. These
are odourless and tasteless capsules. The placebo was pre-
pared by the manufacturer with identical capsules, using non-
fish oils (without omega-3 or omega-6 fatty acids) with the
appropriate colourings and additives to give the placebo cap-
sules the same consistence and colour.
Each patient was given treatment for 40 days at the beginning
of each study period, and was asked to return all used contain-
ers and unused capsules at the next visit.
Study outcome measures
Main study outcomes
- The use of analgesic drugs and NSAIDs, as recorded in the
patient diary.
Analgesics included paracetamol alone; paracetamol com-
bined with weak opiates (for example, coproxamol or copa-
rein); opiates alone (morphine sulphate, dextropropoxyphene,
or tramadol); low-dose NSAIDs (ibuprofen 200 mg, diclofenac
12.5 mg); short-acting NSAIDs used for analgesia (flurbipro-
fen, tiaprofenic acid), aspirin; analgesic use was measured in
number of tablets equivalent to 500 mg paracetamol or 200
mg ibuprofen used per week. The lowest marketed adult dose
of the drug was considered as approximately equivalent (para-
cetamol 500 mg with or without opiate, ibuprofen 200 mg,
ketoprofen 25 mg, diclofenac 12.5 mg, flurbiprofen 100 mg,
tiaprofenic acid 100 mg, and so on).
- Use of NSAIDs was measured as the number of defined daily
doses (DDD) used over each study period, which were then
summed and studied as mean daily DDD used [23-25]. Drugs
were summed globally. These included traditional non-selec-
tive NSAIDs at usual anti-inflammatory doses, piroxicam (DDD
20 mg), tenoxicam (DDD 20 mg), ketoprofen (DDD 150 mg),
diclofenac (DDD 100 mg), naproxen (DDD 500 mg), sulindac
(DDD 400 mg), ibuprofen (DDD 1200 mg); and the COX2
selective agent: celecoxib (DDD 200 mg); though they could
change the dosage, patients were asked to continue using the
same drugs throughout the study.
- Western Ontario-McMaster University Osteo-Arthritis Index
(WOMAC): Patients' function, stiffness and pain were
assessed at each visit using the WOMAC scales. These
scales explore pain, stiffness and function. They were analyzed
in each of the three dimensions, and globally, by summing the
scores of the individual items.
Secondary outcomes
- Use of slow-acting symptomatic drugs used to treat osteoar-
thritis: diacerhein, soy and avocado unsaponifiables, chondroi-
tin sulphate was measured as DDD per day.
- Gastro-protective drug use, all of which were proton pump
inhibitors, was also measured in DDD per day.
- Tolerability: any treatment-emergent adverse events reported
by the patients were recorded (adverse events not reported
previously or not present during the run-in period, or worsen-
ing during the treatment period), and the overall impact was
classified into five classes: 0: no adverse event noted; 1: no
treatment emergent adverse events; 2: mild and short-lasting
symptoms events during the first days of the first treatment
period after treatment onset; 3: mild symptoms or signs
reported or observed several times during the study period, or
persisting throughout the study period; and 4: manifest signs
or symptoms impacting daily life, or non-mild persistent symp-
toms.
In addition, any serious events according to regulatory defini-
tions were recorded and reported to the relevant authorities.
Statistical analysis
All analyses were done in intention to treat (ITT), using all avail-
able data at each time point and baseline observation carried
forward (BOCF) approach for missing data at M1, M2 and M3.
Quantitative variables were described in terms of mean ± SD,
median and range, qualitative variables in terms of number and
%). Parametric Student t-test or Non-parametric Mann-Whit-
ney U test were used for quantitative variable comparisons,
according to distribution characteristics. Qualitative variables
were compared using Chi-square or Fischer exact test accord-
ing to sample size. Ninety-five percent confidence intervals
were estimated by boostrapping method. WOMAC Scores
were analysed using repeated-measures analysis. Analysis of
the analgesic and NSAID drug utilization was done using
repeated-measures analysis of covariance, using treatment
group, treatment periods, their interaction and including the
WOMAC score as covariate. If the overall tested showed sta-
tistically significant differences between the active and pla-
cebo arms, the successive treatment periods would be
compared. Statistical significance was set at 0.05. All analy-
ses were done with SAS version 8.1 by the statistics group of
the Bordeaux University Department of Pharmacology.
Sample size
The hypothesis was that compared to placebo, the active com-
position would result in a 20% greater decrease in the use of
analgesics or NSAIDs than placebo (main study outcome).
With an alpha risk set at 5%, and a power of 90% to detect
this difference, it was estimated that 35 patients per treatment
arm should be included. To take into account possible drop-
outs and missing data, it was decided to include 40 patients
per study arm.Arthritis Research & Therapy    Vol 11 No 6    Jacquet et al.
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Results
Ninety-five patients were eligible for pre-inclusion. Of these 14
were excluded during the pre-inclusion period, for personal
reasons (n = 9), for insufficient severity of OA (n = 3), for
excess severity of OA resulting in hospitalization (n = 1), for
severe depression resulting in psychiatric hospitalization dur-
ing the pre-inclusion period (n = 1).
Eighty-one included patients were therefore randomized to
active treatment (41 subjects) or placebo (40 subjects).
Five patients did not complete the study: one in the active
treatment group because of an adverse event (diarrhoea with
positive rechallenge); four in the placebo group: two for lack
of treatment effect, one for adverse event (vomiting and epi-
gastric pain), and the last became pregnant and was excluded
from the study. All dropped out before the end of the first study
month. None contributed any data to the study beyond inclu-
sion. Patient disposition is shown in Figure 1.
In the active treatment group there were 14 men and 27
women, mean age was 56.8 years, (range 28 to 79). In the pla-
cebo group there were 12 men and 28 women, mean age was
57.5 (range 28 to 84). Overall 41 patients were fully assessa-
ble in the active treatment group, vs. 40 in the placebo group.
The patients who dropped out of the study were not different
from those who completed the study. Two patients, one in
each study group, were wrongly included, their age (28) being
below the inclusion limit. Both had post-traumatic knee OA,
radiologically confirmed with osteophytes, combined with
overweight. Removing them from the study did not change
study results. One 84 year-old patient was above the age
range.
There was no difference between the active and placebo
groups for initial distribution of any of the studied parameters
(Table 1).
Use of analgesics and NSAIDS
Initial use of analgesics or NSAIDs is shown in Table 1. All
patients used at least one or the other: overall 69 of the 81
patients used common analgesics (mostly paracetamol alone
or combined, less frequently opiates, low-dose NSAIDs or
aspirin), using about 19.4 tablets equivalent to 500 mg para-
cetamol or 200 mg ibuprofen per week during the month of
pre-inclusion; about half used NSAIDs at anti-inflammatory
doses, and took slightly more than one DDD per day during the
month pre-inclusion. Only 14 patients used morphine or other
opioids at inclusion.
Over the study period, the mean use of analgesics in the active
arm (6.5 PET/week) vs. the placebo arm (16.5 PET/week) was
significantly different (P < 0.001) with a group mean differ-
ence of -10.0 (95% CI: -4.9 to -15.1). It decreased signifi-
cantly and regularly in patients treated with active treatment,
from a mean of 19.8 tablets per week at baseline to 6.5 tablets
per week at the end of the study, whereas on placebo there
was only an initial decrease, from 19.1 to 16.5 tablets per
week (Figure 2). The difference between the active and pla-
cebo arms was significant (P < 0.001) from the second month
onwards.
After a three-months follow-up, the mean use of NSAIDs in the
active arm (0.36 DDD/day) vs the placebo arm (1.03 DDD/
day) was significantly different (P = 0.02) with a group mean
difference of -0.67 (95% CI: -0.16 to -1.18). Mean daily use of
NSAIDs decreased in the active arm from 1.30 at baseline to
0.36 DDD/day (Figure 3) at three months. In the placebo arm
it decreased from 1.13 to 1.03 DDD/day.
There was no change in the mean use of gastro-protective
agents (data not shown), which concerned only eight patients
in each group.
At the end of the study, the mean use of concomitant slow-act-
ing treatment of osteoarthritis (chondroitin sulphate, diacer-
hein, soy and avocado insaponifiables) in the active arm (0.51
DDD/day) vs the placebo arm (0.73 DDD/day) was not signif-
icantly different (P = 0.82) with a group mean difference of -
0.22 (95% CI: 0.13 to -0.58).
Figure 1
Patient disposition in the study (CONSORT diagram) Patient disposition in the study (CONSORT diagram).
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In the active arm, it decreased from 1.13 ± 0.51 DDD/day pre-
treatment to 1.09 ± 0.52, 0.66 ± 0.50 and 0.51 ± 0.47 after
one, two and three months of active treatment respectively (P
respectively 0.51, 0.001 and 0.001 compared to pre-treat-
ment). In placebo-treated patients, the values were 0.93 ±
0.44 pre-treatment, and 0.81 ± 0.51, 0.70 ± 0.45 and 0.73 ±
0.52 after one, two and three months, none of these being sig-
nificantly different from pre-treatment values. Differences from
baseline in the use of these drugs at the third month were sig-
nificant (P = 0.020) between the active and placebo treat-
ments.
Symptoms of osteoarthritis
At the end of the study (third month), mean WOMAC scores
for pain, stiffness and function in the active arm (respectively
86.5, 41.4 and 301.6) vs the placebo arm (respectively 235.3,
96.3 and 746.5) were all significantly different (P < 0.001)
with group mean differences respectively of -148.8 (95% CI:
-97.7 to -199.9), -54.9 (95% CI: -27.9 to -81.9) and -444.8
(95% CI: -269.1 to -620.4). The mean WOMAC global score
in the active arm (430.1) vs the placebo arm (1085.4) was sig-
nificantly different (P < 0.001) with a group mean difference of
-655.2 (95% CI: -405.4 to -905.1).
Overall WOMAC scores did not change over the course of the
study in the placebo-treated patients, whereas they decreased
by more than half in active treatment patients (Figure 4). The
difference between the active and placebo arms was signifi-
cant from the second month on. The same pattern was found
for each of the individual WOMAC score groups (Table 2).
Tolerability and safety
Fourteen patients reported adverse events with the active
treatment, one of which, diarrhoea with positive rechallenge
starting on the second study day, led to withdrawal from the
study. Two patients complained of eructations smelling of fish-
oil, with soft stools in one. Other adverse events were pain
(five patients: sciatic, sacral, lumbar, dental, scapular), infec-
Table 1
Patient characteristics at inclusion
Phytalgic® Placebo
Total number of subjects 41 40
Male/female 14/27 12/28
Mean Age (range), years 56.8 (28 to 79) 57.5 (28 to 84)
Osteoarthritis (n)
One knee 13 21
Two knees 12 8
One hip 85
Two hips 34
Knees and hips 52
WOMAC scores at inclusion
(mean ± SD)
Pain score 215.7 ± 88.0 229.5 ± 112.1
Stiffness score 98.6 ± 50.6 97.9 ± 63.2
Function score** 688.8 ± 281.0 689.0 ± 368.9
Total score** 1000.8 ± 391.5 1014.6 ± 526.8
Ongoing treatment (n)
Analgesics (number of users, tablets/week ± SD) 34 (19.8 ± 12.7) 35 (19.1 ± 14.4)
Single-component Paracetamol 12 (21 ± 14.7) 15 (15.4 ± 10.4)
Combined Paracetamol 19 (15.6 ± 10.9) 17 (15.1 ± 12.1)
NSAIDs: n (DDD ± SD) 23 (1.3 ± 0.9) 23 (1.1 ± 1.1)
OA Treatment*: n (DDD ± SD) 16 (1.1 ± 0.5) 12 (0.9 ± 0.4)
*OA treatment: slow-acting drugs such as diacerhein, glucosamine, chondroitin sulphate...
DDD: defined daily doses; WOMAC: Western Ontario-Macmaster University Osteoarthritis scores;
**Four patients with missing scores at baseline (two patients in each group)
Values are numbers of patients, or mean value ± SD unless otherwise indicated. There was no significant difference between the randomized 
study groups.Arthritis Research & Therapy    Vol 11 No 6    Jacquet et al.
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tion (three patients: common cold, cystitis, lymphangitis), falls
(two patients), muscle pains (one patient). All were transient
and resolved with or without treatment.
Thirteen patients reported 15 adverse events during placebo
treatment: these were gastroenteritis (n = 1), hypercholester-
olemia (n = 1), hospitalization for systematic screening colon-
oscopy (two persons, both negative), dental problems (n = 3)
and dental bone graft (n = 1), pregnancy (n = 1), lumbar pain
(n = 1), heartburn (n = 1), cystitis (n = 1), diarrhoea (n = 1),
left calf pain presumed venous (n = 1), vomiting and upper GI
pain (n = 1): in this patient all analgesic and NSAID treatment
and study treatment were stopped and this patient was with-
drawn from the study.
Discussion
This randomized double blind placebo-controlled clinical trial
of Phytalgic®, a composition marketed as a food supplement,
showed that after three months patients randomized to Phytal-
gic® used fewer concomitant analgesics and NSAIDs than
patients randomized to placebo, and had better WOMAC
scores. This effect increased regularly over the whole study
period. There were no adverse reactions attributed to the drug
other than digestive (flatulence and diarrhoea, fish-smelling
eructations). The prespecified endpoints were reached and
the study can be seen as a first demonstration of an effect of
this product, confirming anecdotal reports of patient improve-
ment and decreased use of NSAIDs, and the validity of some
recommendations [22].
Even though this is the first known trial of this specific combi-
nation, so that we really did not know what to expect, the mag-
nitude of the effect we found, which is homogeneous over the
different metrics used, was greater than we expected. The
study had been powered to detect a 20% difference in the use
of NSAIDs and analgesics over the study period. What we
found was a greater than 50% reduction in the use of analge-
sics and NSAIDs.
We attempted to avoid the more common biases: Treatment
allocation was random, and conformed to the usual methodol-
ogy of clinical trials; the study was double-blinded, placebo
and active treatments were identical in all respects. Though
two patients on active treatment did complain of fish-smelling
burping that might compromise blinding in these patients,
removing them from the statistical analysis did not change the
results of the study. Of course, this being a single-centre study
should not be considered as definitive proof. Further, large
scale studies will be needed to confirm these results, and pos-
sibly clarify optimal dosing and duration of treatment, maybe
identify responders and non-responders, and so on.
Figure 2
Mean use of analgesics per week in active and placebo-treated patients Mean use of analgesics per week in active and placebo-treated 
patients. (Mean number of tablets per week ± SEM). Preinclusion: the 
month before inclusion. M1, M2, M3, results after respectively one, two 
and three months of treatment.
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Figure 3
Mean use of NSAIDs in DDD per day in active and placebo-treated  patients (Mean number of DDD per day ± SEM) Mean use of NSAIDs in DDD per day in active and placebo-treated 
patients (Mean number of DDD per day ± SEM). Preinclusion: the 
month before inclusion. M1, M2, M3, results after respectively one, two 
and three months of treatment.
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Total WOMAC scores (mean ± SEM) at preinclusion and after one, two  or three months of treatment Total WOMAC scores (mean ± SEM) at preinclusion and after one, two 
or three months of treatment. Randomized to active or placebo treat-
ment. Difference from preinclusion was significant at all subsequent 
times for active, but not for placebo.
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We included run-of-the-mill patients with diverse manifesta-
tions of OA: unilateral or bilateral osteoarthritis of the knee
and/or hip, which is an advantage and a drawback: an advan-
tage because it can be seen as a real-life population, increas-
ing generalisability of the results, a drawback because the
patients were heterogeneous. Even though there did not
appear to be any difference in response between patients with
knee of hip OA, the numbers in each group were not sufficient
for subgroup analysis. Any differential response between hip
and knee OA would need to be explored in further studies.
The composition tested here, Phytalgic®, was devised empiri-
cally, from products used traditionally to treat osteoarthritis. It
has been used commercially for several years, and the present
study was initiated following patient reports of activity. The
exact mechanism of action of the composition remains
unknown, as are its possibly active components. Most of the
components of Phytalgic® are commonly used in practice
[21,26], but clinical trials are few and often of low methodolog-
ical quality. This specific combination has never to our knowl-
edge been tested before in a randomized double-blind clinical
trial, though individual components may have been: Fish oils
and oils rich in omega-3 and/or omega-6 fatty acids are
thought to have a possible effect on rheumatoid arthritis [27]
and osteoarthritis [18], with experimental support [28]. A clin-
ical trial of cod oil in osteoarthritis however found no clear
effect [29], but the oils in the present composition come from
cold-water fish rich in omega-3 and fatty acids (mackerel, her-
ring, from the southern Pacific). Zinc is one of the essential ele-
ments for chondrocyte function, and has been associated with
decreased inflammation [30] and interleukin production [31],
but this would affect patients with rheumatoid arthritis more
than those with OA. Nettles (Urtica dioica) are commonly used
to treat osteoarthritis [26,32]. They may have an analgesic
effect [33], and have also been found to reduce the use of
NSAIDs in patients with osteoarthritis [34]. Selenium (from
Urtica dioica) alone or associated with vitamins A, C, E has
been thought to modify the symptoms or the evolution of OA
[35], but recent clinical trials and meta-analyses are rather
negative in this regard [36,37].
Despite these mixed results and the calls for more clinical trials
such as this one [21], there seems to be an agreement that
fish-oil and essential minerals are appropriate to use in
patients with OA, and in this respect the preparation tested
here appears to correspond with recommendations [22].
The effect of the present combination may be related to any
one of the individual components, or more probably to the
association of these compounds, since none of the com-
pounds used alone seem to have demonstrated effects of the
magnitude found here.
Osteoarthritis is a debilitating disease that is not usually by
itself life-threatening, but is painful and crippling, and severely
degrades quality of life. Its treatment is mainly symptomatic,
using analgesics and non-steroidal anti-inflammatory drugs,
whose adverse effects (mostly digestive or renal, but also pos-
sibly vascular) are such that they may in fact be one of the main
life-threatening risks of the disease. Because of these risks
inherent in the analgesic and anti-inflammatory drugs,
decreasing drug use, especially of NSAIDs, could be a rele-
vant treatment endpoint. However, reduced use of analgesics
should not be associated with increased pain or reduced qual-
Table 2
WOMAC scores at M3 in patients receiving Phytalgic® and those receiving placebo
Phytalgic®
n = 41
Placebo
n = 40
Difference
Phytalgic® - Placebo
P
Pain
Mean (± std) 86.5 ± 94.3 235.3 ± 136.2 -148.8 ± 26.1 <0.001
[95% CI] [56.2; 116.9] [194.2; 276.5] [-97.7; -199.9]
Stiffness
Mean (± std) 41.4 ± 49.7 96.3 ± 71.0 -54.9 ± 13.8 <0.001
[95% CI] [25.6; 57.2] [74.5; 118.2] [-27.9; -81.9]
Function*
Mean (± std) 301.6 ± 315.6 746.5 ± 462.8 -444.8 ± 89.6 <0.001
[95% CI] [200.1; 403.1] [603.1; 890.0] [-269.1; -620.4]
Total*
Mean (± std) 430.1 ± 448.6 1085.4 ± 654.1 -655.2 ± 127.5 <0.001
[95% CI] [285.0; 575.1] [882.0; 1288.9] [-405.4; -905.1]
*four patients with missing scores at baseline, M1, M2 and M3 (two patients in each group).Arthritis Research & Therapy    Vol 11 No 6    Jacquet et al.
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ity of life, but should indicate in fact less need of the drugs.
This is clearly the case here: there is in our study an improve-
ment of WOMAC scores, in all three areas covered by the
scores. This symptomatic improvement was regular and
increased over time, and in parallel the use of analgesics and
NSAIDs decreased substantially.
WOMAC scores did not change much over the course of the
study in the placebo group, though the use of analgesics and
NSAIDs decreased by 20-30%. Though an improvement in
OA scores with placebo is common, this is usually found in tri-
als of single treatments, when a new treatment is given as a
replacement of previous treatment or as new-onset treatment.
In our patients, usual treatment was pursued. The fact that our
patients were treated with analgesics and NSAIDs at baseline
may also explain the relative modesty of the baseline WOMAC
scores: These baseline scores are not raw  untreated OA
scores, but those obtained under usual, recognized effective
treatment.
Conclusions
This is the first randomized clinical trial of this compound. Its
results need to be confirmed in other, multicentre studies, and
in more varied types of OA patients, to ensure these findings
are not just the result of some undetected bias, or a statistical
fluke, however homogeneous and consistent they may seem.
If these results are confirmed, longer-term studies will be
needed to test for the persistence of this effect. Studies in
wider populations will also indicate any real gain in terms of
avoided adverse reactions because of less use of analgesics
and NSAIDs. Considering the size of our population and the
duration of our study, we could not demonstrate this endpoint,
nor did we expect to.
In the meantime, this study demonstrates that use of three
capsules a day over three months of this nutraceutical com-
pound might decrease disease scores in patients with oste-
oarthritis of the knee and/or hip, and reduce their use of
analgesics and NSAIDs.
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